<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03595202</url>
  </required_header>
  <id_info>
    <org_study_id>TS143-01-03</org_study_id>
    <nct_id>NCT03595202</nct_id>
  </id_info>
  <brief_title>Clinical Study of TS-143 in Healthy Adult Male Subjects (Multiple-Dose Administration)</brief_title>
  <official_title>Phase I Clinical Study of TS-143 in Healthy Adult Male Subjects (Multiple-Dose Administration)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taisho Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taisho Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the safety, pharmacokinetics and pharmacodynamics of TS-143 when administered
      3 times a day for 10 days to healthy Japanese adult males using placebo-controlled,
      double-blind, dose escalation study design.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 3, 2017</start_date>
  <completion_date type="Actual">July 7, 2017</completion_date>
  <primary_completion_date type="Actual">July 7, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of subjects with adverse events</measure>
    <time_frame>18 days</time_frame>
    <description>To evaluate the safety of TS-143 given single administration in healthy volunteers by incidence of subjects with adverse events which include abnormal electrocardiograms, vital signs, and clinical laboratory parameters.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentrations of unchanged form (ng/mL)</measure>
    <time_frame>13 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinary excretions of unchanged form (ng/mL)</measure>
    <time_frame>12 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum EPO concentration</measure>
    <time_frame>13 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Reticulocyte count</measure>
    <time_frame>13 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma vascular endothelial growth factor (VEGF) concentration</measure>
    <time_frame>13 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum iron (μg／dL)</measure>
    <time_frame>13 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Total iron binding capacity（μg／dL）</measure>
    <time_frame>13 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy Participants</condition>
  <arm_group>
    <arm_group_label>Step1:4㎎ TID</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>TS-143 12mg total dose/day or Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Step2:11㎎ TID</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>TS-143 33mg total dose/day or Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TS-143</intervention_name>
    <description>Subjects should take 4 capsules once and 3 times per day in step 1. Subjects should take 2 capsules once and 3 times per day in step 2.</description>
    <arm_group_label>Step1:4㎎ TID</arm_group_label>
    <arm_group_label>Step2:11㎎ TID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects should take 4 capsules once and 3 times per day in step 1. Subjects should take 2 capsules once and 3 times per day in step 2.</description>
    <arm_group_label>Step1:4㎎ TID</arm_group_label>
    <arm_group_label>Step2:11㎎ TID</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with a BMI of 18.5 to less than 25.0 at the time of the screening tests

          -  Subjects judged by the principal investigator or a subinvestigator to be appropriate
             for participation in the study based on the results of the screening tests and the
             tests conducted before the investigational drug treatment on Day 1

          -  Subjects capable of receiving an explanation of this study before participation,
             understanding the details, and providing written informed consent themselves

        Exclusion Criteria:

          1. Subjects meeting any of the following criteria in the results of screening tests,
             tests conducted on the day before the first investigational treatment (Day -1), and
             tests conducted before the investigational drug treatment on the morning of Day 1:

               -  Red blood cell count: ≥535 × 10^4 /μL

               -  Hemoglobin: ≥16.2 g/dL

               -  Hematocrit: ≥47.5%

               -  Reticulocyte rate: Outside of the reference value range

          2. Subjects meeting any of the following criteria in the screening tests:

               -  Serum EPO concentration: Outside of the reference value range

               -  Ferritin: ≤30 ng/mL or &gt;upper limit of the reference value

          3. Subjects meeting any of the following criteria in the vital signs in the screening
             tests and the tests conducted before the investigational drug treatment on the morning
             of Day 1:

               -  Blood pressure: Systolic blood pressure ≥140 mmHg, or diastolic blood pressure
                  ≥90 mmHg

               -  Pulse rate: &lt;40 bpm, or ≥100 bpm

               -  Body temperature: ≥37.5°C
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shigeru Okuyama</last_name>
    <role>Study Director</role>
    <affiliation>Taisho Pharmaceutical Co., Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Taisho Pharmaceutical Co., Ltd selected site</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>April 18, 2018</study_first_submitted>
  <study_first_submitted_qc>July 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2018</study_first_posted>
  <last_update_submitted>July 20, 2018</last_update_submitted>
  <last_update_submitted_qc>July 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

